Cantor Fitzgerald Forecasts Reduced Earnings for GH Research

GH Research PLC (NASDAQ:GHRS) – Stock analysts at Cantor Fitzgerald decreased their FY2025 earnings per share (EPS) estimates for shares of GH Research in a note issued to investors on Monday, May 12th. Cantor Fitzgerald analyst C. Duncan now forecasts that the company will earn ($0.84) per share for the year, down from their previous forecast of ($0.79). Cantor Fitzgerald currently has a “Overweight” rating and a $14.00 target price on the stock. The consensus estimate for GH Research’s current full-year earnings is ($0.80) per share.

GHRS has been the subject of several other reports. Guggenheim lowered their price target on GH Research from $32.00 to $29.00 and set a “buy” rating for the company in a research report on Friday, May 9th. Royal Bank of Canada started coverage on GH Research in a research report on Friday, March 7th. They issued an “outperform” rating and a $31.00 target price for the company. HC Wainwright reissued a “buy” rating and set a $40.00 price target on shares of GH Research in a research report on Friday, May 9th. Finally, Stifel Nicolaus upped their target price on shares of GH Research from $18.00 to $32.00 and gave the stock a “buy” rating in a research note on Thursday, February 27th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $30.43.

GH Research Stock Performance

GH Research stock opened at $9.98 on Wednesday. The company has a market capitalization of $519.24 million, a PE ratio of -12.63 and a beta of 0.86. GH Research has a fifty-two week low of $6.00 and a fifty-two week high of $20.50. The firm has a 50 day moving average price of $10.28 and a 200 day moving average price of $9.89.

GH Research (NASDAQ:GHRS) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.19) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.61) by $0.42.

Hedge Funds Weigh In On GH Research

Large investors have recently bought and sold shares of the stock. BNP Paribas Financial Markets purchased a new position in GH Research during the 4th quarter worth approximately $44,000. Palumbo Wealth Management LLC acquired a new stake in shares of GH Research in the first quarter valued at approximately $142,000. XTX Topco Ltd purchased a new position in shares of GH Research during the first quarter worth approximately $169,000. Two Sigma Investments LP purchased a new stake in GH Research in the 4th quarter valued at $117,000. Finally, Millennium Management LLC acquired a new stake in GH Research during the 4th quarter worth $145,000. Institutional investors and hedge funds own 56.90% of the company’s stock.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).